11月19日，康缘药业盘中下跌2.06%，截至13:18，报15.20元/股，成交8470.28万元，换手率0.97%，总 市值86.06亿元。 资金流向方面，主力资金净流出643.92万元，大单买入1109.59万元，占比13.10%，卖出1753.51万元， 占比20.70%。 截至9月30日，康缘药业股东户数4.05万，较上期增加17.20%；人均流通股13969股，较上期减少 14.68%。2025年1月-9月，康缘药业实现营业收入23.43亿元，同比减少24.66%；归母净利润2.00亿元， 同比减少44.10%。 责任编辑：小浪快报 资料显示，江苏康缘药业股份有限公司位于江苏省连云港市经济技术开发区江宁工业城，成立日期1996 年5月8日，上市日期2002年9月18日，公司主营业务涉及涉及药品的研发、生产与销售。主营业务收入 构成为：口服类58.68%，注射类33.28%，外用类8.04%。 康缘药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中药、禽流感药物、医药电 商、抗流感、小盘等。 分红方面，康缘药业A股上市后累计派现9.48亿元。近三年，累计派现3.45亿元。 机构持仓方 ...

11月17日，康缘药业盘中下跌2.01%，截至09:49，报16.06元/股，成交9313.95万元，换手率1.01%，总 市值90.93亿元。 资金流向方面，主力资金净流出248.13万元，特大单买入693.95万元，占比7.45%，卖出661.12万元，占 比7.10%；大单买入1504.77万元，占比16.16%，卖出1785.73万元，占比19.17%。 康缘药业所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：中药、禽流感药物、医药电 商、抗流感、证金汇金等。 截至9月30日，康缘药业股东户数4.05万，较上期增加17.20%；人均流通股13969股，较上期减少 14.68%。2025年1月-9月，康缘药业实现营业收入23.43亿元，同比减少24.66%；归母净利润2.00亿元， 同比减少44.10%。 康缘药业今年以来股价涨17.91%，近5个交易日涨1.90%，近20日涨3.81%，近60日跌9.01%。 资料显示，江苏康缘药业股份有限公司位于江苏省连云港市经济技术开发区江宁工业城，成立日期1996 年5月8日，上市日期2002年9月18日，公司主营业务涉及涉及药品的研发、生产与销售。 ...

Core Viewpoint - Kangyuan Pharmaceutical's stock has shown a mixed performance in recent months, with a year-to-date increase of 17.47% but a decline of 7.08% over the past 60 days, indicating volatility in its market position [1]. Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion yuan, representing a year-on-year decrease of 24.66%. The net profit attributable to shareholders was 200 million yuan, down 44.10% compared to the previous year [1]. - The company has distributed a total of 949.8 million yuan in dividends since its A-share listing, with 345 million yuan distributed over the last three years [2]. Stock Market Activity - As of November 14, the stock price of Kangyuan Pharmaceutical was 16.00 yuan per share, with a market capitalization of 9.059 billion yuan. The stock experienced a 2.04% increase during the trading session [1]. - The trading volume indicated a net inflow of 2.1421 million yuan from main funds, with large orders accounting for 20.99% of purchases and 15.69% of sales [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 17.20% to 40,500, while the average number of circulating shares per person decreased by 14.68% to 13,969 shares [1]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 14.478 million shares, an increase of 440,200 shares from the previous period [2]. Business Overview - Kangyuan Pharmaceutical, established on May 8, 1996, and listed on September 18, 2002, is primarily engaged in the research, production, and sales of pharmaceuticals. Its revenue composition includes 58.68% from oral medications, 33.28% from injections, and 8.04% from external applications [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1].

Core Viewpoint - Kangyuan Pharmaceutical's stock has shown fluctuations with a year-to-date increase of 11.38%, but recent performance indicates a decline over the past 60 days by 10.82% [1] Group 1: Stock Performance - As of November 7, Kangyuan Pharmaceutical's stock price reached 15.17 CNY per share, with a trading volume of 73.44 million CNY and a turnover rate of 0.86% [1] - The stock has experienced a net outflow of 429,200 CNY from main funds, with large orders showing a buy of 11.98 million CNY and a sell of 12.21 million CNY [1] - Over the last five trading days, the stock has increased by 1.47%, while it has decreased by 1.56% over the last 20 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion CNY, representing a year-on-year decrease of 24.66% [2] - The net profit attributable to shareholders for the same period was 200 million CNY, down 44.10% compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangyuan Pharmaceutical increased to 40,500, marking a rise of 17.20% [2] - The average number of circulating shares per person decreased by 14.68% to 13,969 shares [2] - The company has distributed a total of 949.8 million CNY in dividends since its A-share listing, with 345 million CNY distributed over the last three years [3]